HiberCell
HiberCell is a New York biotech working on the biology of dormant, disseminated cancer cells; its yeast beta-glucan immunotherapy imprime PGG, inherited from Biothera, reached late-stage trials with checkpoint inhibitors.
Overview
HiberCell, founded in 2019 in New York, develops therapies against cancer dormancy and relapse and acquired Biothera Pharmaceuticals, whose imprime PGG, a yeast-derived beta-glucan that primes innate immune cells, had been tested with pembrolizumab in breast cancer and melanoma. Its PERK inhibitor and other programmes are in early trials, and the Biothera-era phase 3 record sits on ClinicalTrials.gov under the company as lead sponsor.
Similar pages
not linked directly; found by shared links- CompanyGeorgiamune
Shares Pivotal (registrational) trial, Clinical trial, Melanoma and the tag ctgov-sponsor.
- CompanyCSL Limited
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyD3 Bio (Wuxi)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyDong-A ST
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEndo (now Keenova Therapeutics and Par Health)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEurofarma
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyGrifols
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyInsys Therapeutics
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.